Scott Henry
Stock Analyst at Alliance Global Partners
(2.16)
# 1,512
Out of 4,667 analysts
59
Total ratings
41.18%
Success rate
-4.19%
Average return
Main Sectors:
Stocks Rated by Scott Henry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VVOS Vivos Therapeutics | Maintains: Buy | $8.25 → $6 | $2.89 | +107.61% | 4 | Nov 19, 2024 | |
| LPCN Lipocine | Initiates: Buy | $10 | $4.71 | +112.31% | 1 | Sep 24, 2024 | |
| ASRT Assertio Holdings | Initiates: Buy | $2.75 | $0.95 | +189.47% | 1 | May 28, 2024 | |
| DERM Journey Medical | Initiates: Buy | $8.5 | $5.23 | +62.52% | 2 | Feb 16, 2024 | |
| RNXT RenovoRx | Initiates: Buy | $4 | $1.19 | +236.13% | 3 | Feb 2, 2024 | |
| FBIO Fortress Biotech | Maintains: Buy | $30 → $15 | $1.57 | +855.41% | 2 | Nov 29, 2023 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $12 | $1.22 | +887.65% | 2 | Oct 30, 2023 | |
| CSBR Champions Oncology | Maintains: Buy | $9 → $7.5 | $4.32 | +73.61% | 2 | Sep 22, 2023 | |
| DCTH Delcath Systems | Maintains: Buy | $10 → $13 | $9.63 | +34.99% | 4 | Aug 16, 2023 | |
| VKTX Viking Therapeutics | Maintains: Buy | $19 → $24 | $51.53 | -53.43% | 2 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $111.56 | -19.33% | 9 | Dec 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 → $16 | $21.15 | -26.71% | 2 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $58 | $103.44 | -43.93% | 6 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $36 | $52.08 | -30.88% | 1 | Aug 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $11 | $1.74 | +532.18% | 3 | May 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $6 | $8.94 | -32.89% | 2 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $288 | $4.23 | +6,696.69% | 1 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.21 | - | 1 | Dec 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 | $4.92 | +42.28% | 3 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $0.19 | - | 5 | Apr 18, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.71 | - | 2 | Mar 26, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.65 | - | 1 | Nov 10, 2017 |
Vivos Therapeutics
Nov 19, 2024
Maintains: Buy
Price Target: $8.25 → $6
Current: $2.89
Upside: +107.61%
Lipocine
Sep 24, 2024
Initiates: Buy
Price Target: $10
Current: $4.71
Upside: +112.31%
Assertio Holdings
May 28, 2024
Initiates: Buy
Price Target: $2.75
Current: $0.95
Upside: +189.47%
Journey Medical
Feb 16, 2024
Initiates: Buy
Price Target: $8.5
Current: $5.23
Upside: +62.52%
RenovoRx
Feb 2, 2024
Initiates: Buy
Price Target: $4
Current: $1.19
Upside: +236.13%
Fortress Biotech
Nov 29, 2023
Maintains: Buy
Price Target: $30 → $15
Current: $1.57
Upside: +855.41%
Reviva Pharmaceuticals Holdings
Oct 30, 2023
Reiterates: Buy
Price Target: $12
Current: $1.22
Upside: +887.65%
Champions Oncology
Sep 22, 2023
Maintains: Buy
Price Target: $9 → $7.5
Current: $4.32
Upside: +73.61%
Delcath Systems
Aug 16, 2023
Maintains: Buy
Price Target: $10 → $13
Current: $9.63
Upside: +34.99%
Viking Therapeutics
May 3, 2023
Maintains: Buy
Price Target: $19 → $24
Current: $51.53
Upside: -53.43%
Dec 23, 2022
Maintains: Buy
Price Target: $85 → $90
Current: $111.56
Upside: -19.33%
Aug 24, 2022
Downgrades: Neutral
Price Target: $10 → $16
Current: $21.15
Upside: -26.71%
Aug 3, 2021
Maintains: Neutral
Price Target: $55 → $58
Current: $103.44
Upside: -43.93%
Aug 2, 2021
Maintains: Buy
Price Target: $32 → $36
Current: $52.08
Upside: -30.88%
May 12, 2021
Maintains: Buy
Price Target: $9 → $11
Current: $1.74
Upside: +532.18%
Feb 26, 2021
Maintains: Buy
Price Target: $4 → $6
Current: $8.94
Upside: -32.89%
Feb 16, 2021
Maintains: Buy
Price Target: $300 → $288
Current: $4.23
Upside: +6,696.69%
Dec 4, 2020
Downgrades: Neutral
Price Target: n/a
Current: $0.21
Upside: -
Nov 11, 2020
Upgrades: Buy
Price Target: $7
Current: $4.92
Upside: +42.28%
Apr 18, 2019
Upgrades: Buy
Price Target: n/a
Current: $0.19
Upside: -
Mar 26, 2018
Downgrades: Neutral
Price Target: n/a
Current: $0.71
Upside: -
Nov 10, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.65
Upside: -